Global Outlook for Cell Reprogramming and Direct Reprogramming Services and Products Market to 2030, with Company Profiles of Leading Players Including Allele Biotechnology, ALSTEM, Lonza and Stemnovate
Saturday, August 8, 2020
DUBLIN, July 31, 2020 /PRNewswire/ -- The "Cell Reprogramming (iPSC Generation) / Direct Reprogramming Services and Products Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The 'Cell Reprogramming (iPSC Generation)/Direct Reprogramming Services and Products Market, 2020-2030' report features an extensive study of the current market landscape and the future potential of cell reprogramming services and products in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:
-- A review of the overall landscape of cell reprogramming market,
featuring a list of over 30 cell reprogramming (iPSC Generation)/direct
reprogramming service and product providers and a detailed analysis of
these providers based on a number of parameters, such as year of
establishment, company size, geographical location, location of
manufacturing facilities, type of service (iPSC generation and direct
reprogramming), type of offering (in-house development, kit, service,
technology (for licensing) and iPSC lines), type of technology (sendai
virus-based reprogramming, mRNA reprogramming, episomal reprogramming
and other technologies), type of vector used (viral vector, non-viral
vector, mRNA and others), source cell for iPSC generation (fibroblasts,
blood mononuclear cells, unspecified somatic cells and other cells),
target indication(s), type of application (research and therapeutic) and
additional service(s) offered (assay development, cell and tissue
sourcing, cell banking, cell characterization, cell differentiation,
cell sequencing, genome editing and other services).
-- An insightful competitiveness analysis of iPSC generation and direct
reprogramming service providers, based on supplier strength (based on a
company's employee count and years of experience) and service strength
(which takes into account the number of reprogramming technologies
offered, number of source cells used for iPSC generation used, number of
target indications and number of manufacturing facilities).
-- Elaborate profiles of the industry players that offer cell reprogramming
services and products. Each profiles features a brief overview of the
company, its financial information (if available), details on cell
reprogramming approaches, types of cell(s) utilized and differentiated,
target indication(s), other drug discovery services offered, recent
developments and an informed future outlook.
-- A detailed analysis of more than 540 completed, ongoing and planned
clinical studies of various stem cell therapies, highlighting prevalent
trends across various relevant parameters, such as trial registration
year, phase of development, study design, current trial status, leading
industry sponsors (in terms of number of trials conducted), study focus,
type of stem cells, target indication(s), target therapeutic area(s),
enrolled patient population and regional distribution of trials.
-- An analysis of the partnerships that have been established in this
domain since 2016, covering R&D collaborations, licensing agreements,
mergers and acquisitions, product development and/or commercialization
agreements, clinical trial agreements, process development agreements,
and other relevant deals.
-- A list of stem cell therapy developers/manufacturers, generated based on
a detailed analysis of a set of relevant parameters (such as company
size (employee count), type of cell (s), indication count and existing
partnership(s)), which are anticipated to partner with cell
reprogramming service and product providers in the foreseen future.
One of the key objectives of the report was to understand the primary growth drivers and the future opportunity in cell reprogramming (iPSC generation)/ direct reprogramming services and products market. Based on multiple parameters, such as growth of the overall iPSC market, reprogramming cost and annual number of projects for stem cell therapies, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period, 2020-2030.
The report also features the likely distribution of the current and forecasted opportunity within cell reprogramming services and products market across [A] type of technology offered (sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and other technologies), [B] Source cells for iPSC generation (fibroblasts, blood mononuclear cells, unspecified somatic cells and other cells), [C] type of application (research and therapeutic), and [D] key geographical regions (North America, Europe and Asia- Pacific and rest of the world). To account for the uncertainties associated with the development of reprogrammed cells and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. CURRENT MARKET LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Allele Biotechnology
6.4. Applied Biological Materials
6.5. Axol Bioscience
6.6. Creative Bioarray
6.8. FUJIFILM Cellular Dynamics International
6.13. Thermo fisher Scientific
7. CASE STUDY: CLINICAL TRIAL ACTIVITY IN STEM CELL THERAPY DEVELOPMENT
8. PARTNERSHIPS AND COLLABORATIONS
9. LIKELY PARTNERSHIP OPPORTUNITIES
10. MARKET FORECAST
11. EXECUTIVE INSIGHTS
12. CONCLUDING REMARKS
For more information about this report visit https://www.researchandmarkets.com/r/dywciv
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-outlook-for-cell-reprogramming-and-direct-reprogramming-services-and-products-market-to-2030-with-company-profiles-of-leading-players-including-allele-biotechnology-alstem-lonza-and-stemnovate-301103824.html
SOURCE Research and Markets
||Network Solutions Provider, a Leader in Business Technology Optimization and Security, and CyGlass Form a Strategic Partnership to Include CyGlass' Network Defense as a Service Solution in its Product Portfolio | Sep 23, 2020
||Nuance and Microsoft announce the integration of Dragon Ambient eXperience and Microsoft Teams for virtual telehealth consults | Sep 23, 2020
||Surgical Robotic Systems Market to Reach USD 15.01 Bn, Globally, by 2027 at 13.7% CAGR: Allied Market Research | Sep 23, 2020
||Financial Technology Industry Titans Nellie Levchin and Sim Tshabalala Join Motive Partners' Global Advisory Council | Sep 23, 2020
||Luxury Institute: Data Privacy is a Brand Reputation Issue, Not a Compliance Issue | Sep 23, 2020
||Veterinary Software Market to Reach $2.08 Bn, Globally, by 2027 at 6.1% CAGR, Says Allied Market Research | Sep 23, 2020
||Martin UAV Contracted to Support Deployed Marines | Sep 23, 2020
||Consumption Volume and Market Value Trends in the Global Gouda Market | Sep 23, 2020
||YASH Technologies announces partnership with Snowflake | Sep 23, 2020
||RSIP Vision Launches a New Knee Segmentation and Landmark Detection from X-ray Module | Sep 23, 2020